Ukuthunyelwa ngenqanawe ngoKhuseleko CAS 1156491-10-9 (1R,2S)-rel-2-(3,4-Difluorophenyl)cyclopropanamine hydrochloride Eyona Mgangatho iPhantsi ixabiso eliphantsi

I-Ticagrelor sisiyobisi se-antiplatelet yomlomo, igama layo le-brand brand yaseMelika nguBrilinta, kunye negama layo laseYurophu yiBrilique. I-Ticagrelor i-reversible platelet adenosine diphosphate (ADP) i-receptor antagonist eyenzelwe ukuthintela iiplatelet ukuba zibambene kunye nokwenza amacwecwe egazi angakhokelela ekuhlaselweni kwentliziyo kunye nokubetha. E-United States, i-ticagrelor yaqala ukuvunywa yi-FDA ngoJulayi 2011 yonyango lwezigulane zabantu abadala abane-acute coronary syndrome (ACS). Idatha yeklinikhi ibonisa ukuba i-ticagrelor iphumelele kakhulu kune-clopidogrel ekunciphiseni ukufa kwe-cardiovascular kufa ubuncinane kwiinyanga ze-12 emva kwesiganeko se-ACS. Ukongezelela, i-ticagrelorChemicalbook iphinde yanciphisa iziganeko ze-stent thrombosis (ST) kwizigulane ezifumene i-stents ukunyanga i-ACS. NgoJuni 2020, i-AstraZeneca yabhengeza ukuba i-US Food and Drug Administration (FDA) ivume i-anticoagulant Brilinta (ticagrelor) ukuba isetyenziswe kwizigulana ezinengozi ephezulu ye-coronary artery disease (CAD) ukunciphisa umngcipheko wokuhlaselwa yintliziyo yokuqala. okanye umngcipheko wokuhlaselwa sistrowuku. NgoNovemba 2020, i-AstraZeneca yazisa ukuba i-US Food and Drug Administration (FDA) ivume isalathisi esitsha se-anticoagulant Brilinta (ticagrelor), ngokudibanisa ne-aspirin, kunyango lwe-ischemia enzima. Kwizigulane ezine-hemorrhagic stroke okanye i-high-risk transient ischemic attack (TIA), iyanciphisa umngcipheko we-stroke elandelayo.